Inside the research
Neogen Corporation
NEOG Research profile · latest available data
Price overview
$13.76
▲ +0.10 (+0.7%)
| 52w hi | $13.98 |
|---|---|
| 52w lo | $5.36 |
| Vol | 5.22M |
| As of | 25 Sep 2026 |
The Verdict
Our score +2.07
| Short | +4.21 |
|---|---|
| Medium | +1.13 |
| Long | -0.31 |
computed 2026-09-27
Key fundamentals
Neogen Corporation
Healthcare · Medical Devices
| Market cap | $3.00B |
|---|---|
| Enterprise value | $3.63B |
| Forward P/E | 36.21x |
| EV / EBITDA | 38.31x |
| P / S (ttm) | 3.45x |
| Profit margin | -0.9% |
| Return on equity | -0.4% |
| Revenue growth | -0.1% |
| Debt / equity | 38.83 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | -0.04 | |
| Sector | +0.08 | |
| Technical | +0.26 | |
| Earnings | +0.49 | |
| Sentiment | +0.53 |
macro × 1.00 · 2026-09-27
Business overview
Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments. The company offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns for food producers and processors. It also provides reagents and test kits used in immunoassay production, forensic and animal toxicology, and life science research; unique colorimetric and chemiluminescent substrates for research use; veterinary instruments and delivery systems used for administering antibiotics and vaccines under the Ideal and Prima Tech brands; and precision instruments designed for injections, topical and oral administration, artificial insemination, and animal identification for farmers, ranchers, and veterinarian under the Prima Tech brand. In addition, the company offers digestive aids and nutritional supplements; Natural Vitamin E-AD to address vitamin deficiencies in swine, cattle, and sheep; RenaKare; companion animal parasiticides under Provecta brand; BotVax B; EqStim; ImmunoRegulin, used in dogs to assist in managing pyoderma; companion animal parasiticides under the Provecta brand; rodent and insect control products under the Ramik, CyKill, Havoc, Prozap, SureKill, and StandGuard brands. Further, it markets Uniprim, a veterinary antibiotic; operates sgenomics labs offering DNA genotyping, sequencing, and trait analysis for livestock and companion animals; and provides software systems that help testers to analyze and store results and perform analysis on the results from multiple locations over extended periods. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.
Risk Metrics
| Beta vs SPX | 0.41 |
|---|---|
| Corr SPX | 0.11 |
| Annual vol | 61.8% |
| Annual ret | +7.1% |
| Sharpe | 0.12 |
| Max DD | -74.8% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-07 | Officer / Director Change | read |
| 2026-07-30 | Earnings Release, Exhibits | read |
| 2026-04-20 | Reg FD Disclosure, Exhibits | read |
| 2026-04-09 | Earnings Release, Exhibits | read |
| 2026-03-30 | Officer / Director Change | read |
| 2026-01-08 | Earnings Release, Exhibits | read |
| 2025-10-30 | Officer / Director Change, Other Material Event… | read |
| 2025-10-27 | Shareholder Vote, Exhibits | read |
| 2025-10-09 | Earnings Release, Exhibits | read |
| 2025-09-15 | Officer / Director Change, Other Material Event… | read |
| 2025-08-21 | Officer / Director Change, Exhibits | read |
| 2025-08-14 | Officer / Director Change, Other Material Event… | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-14 | Moylan John Patrick | Chief Accounting Officer | Grant | 8.58K | $100.00K |
| 2026-08-14 | Ranalli Tamara A. | Senior Vice President | Grant | 25.75K | $300.00K |
| 2026-08-14 | Stacey Jennifer Evans | Chief Legal Officer | Grant | 38.63K | $450.00K |
| 2026-08-14 | Riggsbee Richard Bryan | CFO | Grant | 51.50K | $600.00K |
| 2026-08-14 | Nassif Mikheal | CEO | Grant | 141.63K | $1.65M |
| 2026-08-04 | Nassif Mikheal | CEO | Buy | 370 | $4.37K |
| 2026-06-03 | Moylan John Patrick | Chief Accounting Officer | Withheld for tax | 2.55K | $22.34K |
| 2026-05-18 | Rocklin Amy M | Former Chief Legal Office | Option exercise | 35.18K | $326.85K |
| 2026-05-18 | Rocklin Amy M | Former Chief Legal Office | Withheld for tax | 10.24K | $95.14K |
| 2026-05-04 | Moylan John Patrick | Chief Accounting Officer | Option exercise | 4.56K | $43.44K |
Flow & Concentration
| Insider 180d net | $4.37K |
|---|---|
| Insider buys / sells | 1 / 0 |
| Insider bias | Neutral |
| 13F holders | 7 |
| Top-5 share | 99.1% |
| HHI | 4,951 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $80.43M | 8.95M |
| Capital Research / Capital World | $15.08M | 1.68M |
| Fidelity / FMR LLC | $10.48M | 1.17M |
| Citadel Advisors | $6.22M | 691.83K |
| AQR Capital Management | $4.49M | 500.36K |
| Renaissance Technologies | $1.06M | 118.24K |
| T. Rowe Price Group | $2.71K | 301.36K |
As of 2026-06-30
SEC Filings
The Long Run
FY 2012–2025 · 14 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $924.22M | +26.4% | |
| Gross profit | $421.38M | +12.4% | |
| Operating income | $37.52M | +0.8% | |
| Net income | -$1.09B | +7.9% | |
| Cash from ops | $35.26M | +4.7% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $13.68 | $13.86 | $13.38 | $13.76 | 5.22M |
| Sep 24 | $13.48 | $14.01 | $13.46 | $13.66 | 3.83M |
| Sep 23 | $14.21 | $14.26 | $13.50 | $13.57 | 3.68M |
| Sep 22 | $13.62 | $14.18 | $13.61 | $13.98 | 4.62M |
| Sep 21 | $13.12 | $13.72 | $12.96 | $13.61 | 4.40M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →